Original paper
P1.01-53 Clinical Utility of Two Different Plasma-Based EGFR Mutation Tests in Patients with Advanced Non-Small Cell Lung Cancer
Abstract
When tumor biopsies from patients (pts) with advanced NSCLC yield infeasible or insufficient for successful molecular subtyping, plasma cfDNA genotyping has been widely adopted due to its convenience and high positive predictive value. However, a different assay sensitivity makes the optimal choice more difficult. In this study, we have analyzed the clinical utility of two different plasma-based EGFR-mutation (mEGFR) tests in pts with advanced...
Paper Details
Title
P1.01-53 Clinical Utility of Two Different Plasma-Based EGFR Mutation Tests in Patients with Advanced Non-Small Cell Lung Cancer
Published Date
Oct 1, 2019
Journal
Volume
14
Issue
10
Pages
S378 - S379
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History